• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Taiho Pharmaceutical

Takeda HQ
Pharma

Takeda, Hutchmed hook up on cancer drug for $1.13B

Takeda has gained commercial rights to Hutchmed's cancer drug fruquintinib outside of China for $400M up front, plus $730M in potential milestones.
Kevin Dunleavy Jan 23, 2023 10:31am
Asia map globe

China's reimbursement talks, Sun, GenScript—Fierce Pharma Asia

Jan 20, 2023 9:00am
Servier

Servier, Taiho's Lonsurf excels in colorectal cancer upgrade

Jan 18, 2023 3:50pm
Asia map globe

J&J-Legend, Takeda, Merck and more—Fierce Pharma Asia

Oct 7, 2022 10:50am
FDA

A third FGFR inhibitor is wading into the bile duct cancer arena

Oct 3, 2022 10:30am
Asia map globe

Takeda, Sun, Aurobindo, Eisai and more—Fierce Pharma Asia

May 13, 2022 9:45am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy